p. 325−338
2476-762X
Vol.8/No.3
p. 339−347
2476-762X
Vol.8/No.3
p. 348−349
2476-762X
Vol.8/No.3
p. 353−356
2476-762X
Vol.8/No.3
p. 357−362
2476-762X
Vol.8/No.3
p. 363−366
2476-762X
Vol.8/No.3
0.05). P value in the relationship with survival and response to Fludarabin was more than 0.05.Above all,Fludarabin is the choice treatment as first and second line therapy, as well as for patients who have failedtherapy with standard regimens.]]>
p. 367−371
2476-762X
Vol.8/No.3
p. 372−374
2476-762X
Vol.8/No.3
50-60 years age groups, the prevalence of PSA levels >4 μg/L were 1.1% and 3.7% respectively. This roserapidly to 11.3% and 23.5% for age groups >60-70 and >80 years respectively. Our study shows that the medianPSA levels in the Caucasian population in the USA are higher than those of Chinese, Malays and Indians inSingapore. PSA levels were positively associated with age. It may be more appropriate to offer PSA testing tomen who are >60 years old rather than the current >50 years.]]>
p. 375−378
2476-762X
Vol.8/No.3
p. 379−382
2476-762X
Vol.8/No.3
p. 383−386
2476-762X
Vol.8/No.3
p. 387−389
2476-762X
Vol.8/No.3
p. 390−394
2476-762X
Vol.8/No.3
p. 395−398
2476-762X
Vol.8/No.3
p. 399−404
2476-762X
Vol.8/No.3
p. 405−411
2476-762X
Vol.8/No.3
p. 412−416
2476-762X
Vol.8/No.3
p. 417−421
2476-762X
Vol.8/No.3
p. 422−428
2476-762X
Vol.8/No.3
p. 429−435
2476-762X
Vol.8/No.3
p. 436−437
2476-762X
Vol.8/No.3
p. 438−444
2476-762X
Vol.8/No.3
p. 445−451
2476-762X
Vol.8/No.3
p. 452−456
2476-762X
Vol.8/No.3
p. 457−461
2476-762X
Vol.8/No.3
p. 462−463
2476-762X
Vol.8/No.3
p. 464−465
2476-762X
Vol.8/No.3